Serum levels of pyridinium crosslinks in postmenopausal women and in Paget's disease of bone.
The purpose of this study was to measure pyridinium crosslinks in serum by high performance liquid chromatography (HPLC) and to correlate levels with urinary excretion in patients with different osteometabolic conditions. Blood and spot urine samples were collected between 9 and 11 A.M. in 92 early postmenopausal, untreated women (age 52.3 +/- 2.6 years, months since menopause 20.4 +/- 9.6), 17 patients with active Paget's disease (10 males, aged 65. 1 +/- 12.6) and 24 healthy premenopausal women (aged 28.4 +/- 4.2). Urinary excretion of the total fraction (free + peptide bound) of pyridinolines (Pyr, Dpyr) was measured by HPLC. Before HPLC analysis, serum samples were submitted to a clean-up procedure by ultrafiltration. In 42 postmenopausal women, bone loss was calculated from two bone mass measurements (L2-L4, DXA), performed at study entry and after 12 months. Statistical analysis was performed by Student's t test for independent samples and linear regression analysis. In pagetic patients' serum levels of Pyr and Dpyr were more than threefold increased over the mean observed in healthy controls and were closely correlated with total alkaline phosphatase levels (Pyr: r = 0.73; Dpyr: r = 0.72, P < 0.0005). Compared with controls, postmenopausal women had significantly increased levels of both urinary and serum Pyr and Dpyr (P < 0.003). In pagetic patients and postmenopausal women, crosslinks serum levels were correlated with their urinary excretion with r values ranging from 0.46 to 0.84. In postmenopausal women, only serum Dpyr correlated with the rate of bone loss (r = -0.36, P = 0.02). The data suggest that serum levels of pyridinium cross-links are correlated with urinary excretion in patients with different osteometabolic conditions. The determination of serum levels prevents limitations related to urinary specimen collection and may be a more practical method for routine application, avoiding corrections for urinary creatinine which could be misleading.
Sinigaglia
L
L
Chair of Rheumatology, Gaetano Pini Institute, Milan, Italy.
Varenna
M
M
Binelli
L
L
Beltrametti
P
P
Zucchi
F
F
Arrigoni
M
M
Frignani
S
S
Abbiati
G
G
D015502:Absorptiometry, Photon; D000328:Adult; D000368:Aged; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density; D002851:Chromatography, High Pressure Liquid; D003432:Cross-Linking Reagents; D005260:Female; D006801:Humans; D016014:Linear Models; D008159:Lumbar Vertebrae; D008297:Male; D008875:Middle Aged; D010001:Osteitis Deformans / Q000097:blood* / Q000652:urine; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000652:urine; D017697:Premenopause; D011726:Pyridinium Compounds / Q000097:blood* / Q000652:urine
D015415:Biomarkers; D003432:Cross-Linking Reagents; D011726:Pyridinium Compounds